ANN ARBOR, MI – A groundbreaking study spearheaded by researchers at University of Michigan Health has shed critical new light on a common, yet often unaddressed, aspect of living with Multiple Sclerosis (MS): the use of psychoactive substances for symptom management, recreation, and socialization. The comprehensive investigation reveals that while many commonly consumed substances may offer immediate, sought-after relief for debilitating symptoms like fatigue or pain, they frequently come with a complex array of concurrent or subsequent adverse effects, ultimately creating a challenging paradox for individuals seeking comfort.
The study, led by Dr. Anna Kratz, a professor of Physical Medicine and Rehabilitation at University of Michigan Health and head of the Kratz Lab, utilized an innovative real-time assessment method to capture the nuanced experiences of MS patients. Its findings, published in the Archive of Physical Medicine and Rehabilitation, underscore the urgent need for open, non-judgmental dialogue between patients and healthcare providers to better understand and navigate the intricate relationship between psychoactive substance use and MS symptomology.
The Unseen Battle: Symptom Management in Multiple Sclerosis
Multiple Sclerosis is a chronic, often debilitating disease that attacks the central nervous system, comprising the brain, spinal cord, and optic nerves. Its unpredictable nature and wide spectrum of symptoms make it one of the most challenging conditions to manage. Patients often grapple with a constellation of symptoms including profound fatigue, chronic pain, muscle spasticity, cognitive impairment, balance issues, vision problems, and significant emotional distress, including anxiety and depression. These symptoms can fluctuate daily, hourly, and often resist conventional pharmacological treatments.
In the relentless pursuit of relief and a semblance of normalcy, many individuals living with MS explore various strategies, both conventional and unconventional. Among these, the use of psychoactive substances – ranging from widely accepted items like caffeine and alcohol to more controversial ones like cannabis and opioids – is common. Patients may turn to these substances hoping to alleviate pain, reduce stress, combat fatigue, improve sleep, or simply enhance social engagement. The immediate accessibility and perceived effectiveness of these substances can make them an appealing, albeit potentially risky, option for self-management when other avenues have proven insufficient or slow to act.
However, the scientific understanding of how these substances specifically interact with the complex pathophysiology of MS and its diverse symptoms has historically been limited. Much of the existing data relied on retrospective self-reporting, which is prone to recall bias and fails to capture the dynamic, momentary fluctuations in symptoms and substance effects experienced in daily life. This knowledge gap has left both patients and providers ill-equipped to make fully informed decisions regarding their use.
A Novel Approach: Capturing Real-Time Experiences Through EMA
To overcome the limitations of traditional research methodologies, Dr. Kratz and her team employed an ecological momentary assessment (EMA) approach. This innovative methodology allowed researchers to gather data in real-time, providing an unprecedented granular view into the daily lives of individuals with MS. Rather than relying on participants to recall their experiences over extended periods, which can often be inaccurate or incomplete, EMA prompts individuals to report on their current state and behaviors at multiple points throughout the day.
For this study, participants with MS were asked to report on their symptom severity and substance use four times a day over a 14-day period. This intensive data collection schedule provided thousands of individual data points, offering a rich tapestry of information about the interplay between substance intake and symptom fluctuations. Specifically, participants reported their levels of fatigue, pain, stress, and depressive symptoms. Concurrently, they indicated whether they had consumed alcohol, caffeine, nicotine, cannabis, or opioids prior to their symptom ratings.
This rigorous, real-time data collection method allowed the research team to observe immediate and short-term correlations that retrospective studies simply cannot. By linking momentary symptom ratings directly with reported substance use, the study began to uncover intricate patterns, revealing not just the desired immediate effects, but also the often-unforeseen adverse symptoms that emerged in close temporal proximity to substance consumption. This level of detail is crucial for understanding the true, lived experience of MS patients and for developing more effective, personalized management strategies.
Unpacking the Mixed Effects: Substance-Specific Findings
The study’s findings, published in the Archive of Physical Medicine and Rehabilitation, revealed a consistent theme across several commonly used psychoactive substances: a pattern of mixed effects, where immediate relief was often accompanied by the worsening of other symptoms. While the original article provides a summary of these "correlations," it emphasizes the mixed nature of the effects rather than specific quantitative data points for each substance and symptom. However, based on the study’s conclusions and common pharmacological understanding, we can elaborate on the potential implications of these mixed effects for each substance category:
Caffeine: The Double-Edged Boost
For many, a cup of coffee is a daily ritual, a perceived necessity for energy and focus. For individuals with MS battling profound fatigue, caffeine might seem like a natural ally. The study acknowledges this perceived benefit, noting that MS patients, much like the general population, may seek caffeine for a "pick me up." Indeed, an immediate increase in alertness and a temporary reduction in fatigue are common short-term effects of caffeine.
However, the "mixed effects" finding suggests that this immediate boost often comes at a cost. Excessive or poorly timed caffeine intake can lead to increased anxiety, jitters, and most significantly for MS patients, disrupted sleep patterns. Poor sleep, in turn, can exacerbate fatigue, pain sensitivity, and depressive symptoms the following day, creating a vicious cycle. The temporary relief from fatigue might be outweighed by subsequent sleep disturbances, leading to a net negative impact on overall well-being. Furthermore, some individuals may experience a "caffeine crash" as its effects wear off, leading to even more profound fatigue than before consumption.
Alcohol: Fleeting Solace, Lasting Repercussions
Alcohol is frequently used for social lubrication, relaxation, and self-medication for stress or pain. In the context of MS, patients might turn to alcohol for its immediate anxiolytic (anxiety-reducing) or analgesic (pain-relieving) properties. The study’s "mixed effects" indicate that these immediate desired outcomes might indeed occur for some.
However, alcohol’s depressant effects on the central nervous system can quickly turn detrimental for MS patients. Even moderate consumption can significantly worsen fatigue, impair cognitive function (which is already a challenge for many with MS), and disrupt sleep architecture, leading to non-restorative sleep. Furthermore, alcohol can interact negatively with various MS medications, potentially amplifying side effects or reducing drug efficacy. In the long term, regular alcohol consumption can exacerbate depressive symptoms, contribute to nutritional deficiencies, and potentially worsen neurological symptoms or balance issues. The temporary escape it offers from pain or stress may be fleeting, replaced by a cascade of other challenging symptoms.
Nicotine: A Costly Comfort
Nicotine, primarily consumed through smoking, is often associated with stress reduction and a temporary sense of alertness or focus. For individuals dealing with chronic stress and cognitive challenges associated with MS, these effects might be perceived as beneficial.
However, the "mixed effects" of nicotine are particularly concerning given its well-established detrimental health impacts. While a temporary reduction in perceived stress might occur, nicotine’s overall physiological impact is overwhelmingly negative. Beyond the well-known risks of cardiovascular disease and cancer, smoking has been linked to accelerated MS progression and increased disability. Nicotine can also negatively impact sleep quality, and the withdrawal symptoms between doses can contribute to increased irritability and anxiety, negating any short-term stress relief. The study’s findings likely highlight that any momentary psychological benefit is quickly overshadowed by the profound and cumulative adverse effects on both MS symptoms and overall health.
Cannabis: A Complex Landscape of Hope and Hazard
Cannabis use for medicinal purposes, particularly for chronic pain and spasticity, has gained significant traction, and many MS patients report using it for symptom relief. The study’s findings of "mixed effects" for cannabis reflect the complex and often individualized responses to this substance. Patients may experience immediate relief from pain, spasticity, or anxiety, aligning with common anecdotal evidence and some clinical studies.
However, the study also points to potential adverse effects. These can include cognitive impairment, sedation, increased fatigue, and, in some individuals, paradoxical anxiety or paranoia. The psychoactive components of cannabis, particularly THC, can affect memory, concentration, and reaction time, which are already areas of concern for many with MS. The "mixed effects" suggest that while a patient might find temporary relief for one symptom, they could simultaneously experience worsening of another, or develop new challenges such as increased drowsiness during the day. Furthermore, the variability in cannabis strains, dosages, and routes of administration makes its effects highly individual and often unpredictable.
Opioids: Powerful Relief, Significant Risks
Opioids are potent pain relievers, often prescribed for severe chronic pain. For MS patients experiencing intense, intractable pain, opioids can provide significant immediate relief. The study’s inclusion of opioids underscores their use in this population, likely confirming their effectiveness in immediate pain reduction.
Yet, the "mixed effects" observed for opioids are perhaps the most critical to understand due to their substantial risks. While providing powerful pain relief, opioids are associated with a high potential for dependence, addiction, and a range of debilitating side effects including severe constipation, nausea, sedation, and respiratory depression. For MS patients, long-term opioid use can contribute to worsened fatigue, exacerbate cognitive dysfunction, and potentially increase depressive symptoms. The immediate relief from pain may come at the cost of significantly impaired quality of life due to side effects, and the profound challenges associated with long-term use and withdrawal. This highlights the critical need for extreme caution and careful monitoring when opioids are considered for MS pain management.
Bridging the Gap: The Call for Open Dialogue
The implications of these "mixed effects" are profound, particularly for patient care. Dr. Anna Kratz emphasizes the relatable nature of seeking relief: "Just as many people look to a cup of coffee in the afternoon for a pick me up, people with multiple sclerosis may seek caffeine to help with fatigue or alcohol to manage pain." This statement humanizes the patient experience, acknowledging the underlying motivation for self-medication.
The study’s most crucial message revolves around the necessity of open and honest communication between patients and their healthcare providers. "Insights from studies like this could prompt a person with multiple sclerosis to reflect on what they are putting into their bodies and how it is impacting their symptoms," Kratz explains. This self-reflection is a powerful first step, but it must be supported by a trusting clinical environment.
Dr. Kratz strongly encourages patients to discuss all psychoactive substances they are using – habitually, recreationally, or for symptom management – with their providers. Equally important, she urges providers to be "attentive listeners." This means approaching the topic without judgment, understanding that patients are often seeking relief from genuinely debilitating symptoms, and that self-medication is a common coping mechanism.
"Having a better understanding of how these substances impact patients with multiple sclerosis will be beneficial for providers," she asserts. "Patients using psychoactive substances is not going to go away. Being able to understand the role these substances play and the pros and cons of each will allow providers to better advise their patients when it comes to use of these products." This perspective is vital for fostering a collaborative approach to care, moving away from prescriptive dictates and towards shared decision-making. By understanding the immediate perceived benefits and the often-hidden adverse effects, clinicians can offer more personalized, evidence-based guidance, helping patients weigh the true costs and benefits of their choices.
Charting the Future: Implications for MS Care and Research
This seminal study by Dr. Kratz and her team has far-reaching implications, not only for immediate clinical practice but also for the future trajectory of MS research and patient empowerment.
For Clinical Practice:
The findings necessitate a shift in how healthcare providers screen for and discuss substance use with their MS patients. Rather than a cursory question about illicit drug use, conversations should encompass the full spectrum of psychoactive substances, including seemingly innocuous ones like caffeine. Clinics could integrate comprehensive substance use assessments into routine visits, using a non-judgmental framework. This information can then be used to develop personalized symptom management plans that proactively address potential negative interactions or unintended consequences of self-medication. Providers can educate patients about the "mixed effects" phenomenon, helping them to critically evaluate their own experiences and make more informed choices. This might involve suggesting alternative, evidence-based strategies for symptom relief, or advising on safer consumption patterns for certain substances.
For Patient Empowerment:
This research equips patients with valuable knowledge, enabling them to become more active participants in their own care. Understanding that immediate relief might mask underlying or subsequent problems can empower individuals to monitor their symptoms more closely and connect the dots between substance use and their overall well-being. It encourages critical thinking about the long-term efficacy and safety of their self-management strategies, fostering a sense of agency and informed decision-making.
For Future Research:
The EMA methodology employed in this study provides a robust template for future investigations. Key areas for further research include:
- Longitudinal Studies: While this study captured real-time data over 14 days, longer-term studies are needed to understand the cumulative effects of chronic substance use on MS progression and overall quality of life.
- Specific Formulations and Dosages: Particularly for cannabis, research is needed to differentiate the effects of various cannabinoids (THC, CBD, etc.), delivery methods, and dosages on specific MS symptoms.
- Individual Differences: Investigating genetic predispositions, comorbidities, psychological profiles, and socioeconomic factors that might influence individual responses to psychoactive substances.
- Neurobiological Mechanisms: Exploring the underlying neurobiological pathways through which these substances exert their mixed effects in the context of MS pathophysiology.
- Intervention Development: Using these insights to develop and test targeted interventions, including behavioral therapies, mindfulness practices, or novel pharmacological approaches, that can effectively manage MS symptoms without the adverse effects of certain psychoactive substances.
For a Holistic Approach to Care:
Ultimately, this study reinforces the importance of a holistic, multidisciplinary approach to MS management. It highlights that effective care extends beyond prescribed medications to encompass all aspects of a patient’s life, including their self-management practices and choices. By fostering open communication, providing evidence-based education, and supporting shared decision-making, healthcare systems can better serve individuals living with MS, helping them navigate the complexities of their condition with greater clarity and control.
Conclusion
The study from University of Michigan Health represents a significant step forward in understanding the intricate relationship between psychoactive substance use and symptom management in Multiple Sclerosis. By utilizing real-time data collection, Dr. Anna Kratz and her team have illuminated the often-paradoxical nature of these substances, revealing that immediate relief can frequently be accompanied by unforeseen adverse effects. This vital research serves as a powerful call to action for both patients and healthcare providers: to engage in honest, non-judgmental conversations, to prioritize informed decision-making, and to collaboratively pursue comprehensive care strategies that genuinely enhance the well-being and quality of life for individuals living with MS. As Dr. Kratz eloquently states, "Patients using psychoactive substances is not going to go away," making understanding their full impact an imperative for modern MS care.
Additional Authors: Jeeyeon Kim, from the Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI. Dawn M. Ehde, from the Department of Rehabilitation, University of Washington, Seattle, WA. Kevin N. Alschuler, from the Department of Rehabilitation Medicine University of Washington, Seattle, WA and the Department of Neurology, University of Washington, Seattle, WA. Nora E. Fritz, from the Department of Health Care Sciences, Wayne State University, Detroit, MI and the Department of Neurology, Wayne State University, Detroit, MI.
Paper Cited: “Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis,” Archive of Physical Medicine and Rehabilitation. DOI: 10.1016/j.apmr.2026.01.014
